JWCA advises Guardant Health on its $550 million convertible and capped call issuance
November 2026 | read press release
Transaction Background
Guardant Health, Inc. (“Guardant” or the “Company”) raised $550mm convertible debt at attractive terms (0.00% coupon and 35.0% conversion premium), while refinancing ~$395.2mm (80.5%) of the outstanding convertible due 2027
Guardant’s objectives included:
Refinance a majority of convertible due in November 2027
Protect against future equity dilution through derivative overlay
Minimize stock price risk during execution
JWCA provided extensive analysis for Guardant for the transaction, including:
Convertible refinancing scenarios
Accounting implications
Shareholder messaging
Convertible and capped call documentation to ensure maximum value and future efficiency/flexibility
The transaction was conducted privately using a wall cross process, before flipping into an overnight marketed transaction
JWCA designed and ran a capped call auction process to achieve competitive terms
JWCA provided advice, support and analysis throughout the execution process
Results
Guardant’s convertible transaction was very well received by investors:
The transaction reflected strong investor demand in the Company’s offering from investors
The Company was able to achieve a 0.00% fixed coupon and priced at mid point of the wall cross marketed conversion premium range
Refinanced ~80.5% of the Company’s 2027 convertible notes
GH eliminated stock price risk, as the transaction was executed via a confidential wall cross process, and priced overnight with convertible investors
Capped call auction process produced considerable savings for Guardant
